Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Recce Pharmaceuticals Ltd. ( (AU:RCE) ) has provided an update.
Recce Pharmaceuticals Ltd announced a change in the director’s interest, with Dr. John Prendergast acquiring 51,136 fully paid ordinary shares through participation in the company’s pro-rata non-renounceable entitlement offer. This acquisition reflects an increase in Dr. Prendergast’s holdings, potentially signaling confidence in the company’s strategic direction and financial health, which may positively influence stakeholder perception and market positioning.
More about Recce Pharmaceuticals Ltd.
Recce Pharmaceuticals Ltd is a company in the pharmaceutical industry, focusing on the development and commercialization of synthetic anti-infectives aimed at addressing antibiotic-resistant superbugs and emerging viral pathogens.
Average Trading Volume: 217,174
Technical Sentiment Signal: Sell
Current Market Cap: A$82.51M
See more insights into RCE stock on TipRanks’ Stock Analysis page.